- Insight
- Medicare Coverage Gap Discount Program Guidance Beginning in 2011
- CMS Proposed 2011 Policies and Payment Rates for Inpatient Services
- CMS Issues Final 2011 Payment Policies for Medicare Advantage and Prescription Drug Plans
- OPPS 2010 Rule Update
- MPFS 2010 Rule Update
- OIG releases CY 2010 Work Plan – Is your brand at risk?
- Medicare Administrative Contractor Protest Update
- Health Economics and Reimbursement
- The Impact of ICD-10 on MS-DRGs
Health Economics and Reimbursement
As a discipline, health economics draws conceptual distinction between healthcare and global concepts of resource scarcity. However, in today’s changing market, a global focus will not meet the healthcare crisis that is facing the United States. It is estimated that by the year 2030, there will be 80 million Americans enrolled in the Medicare program. As this shift in insurance population threatens the solvency of the Medicare program, a more focused assessment tool, one that links financial benefit to payment for product, is needed. Comparative effectiveness research appears to be the tool to achieve this goal. Comparative effectiveness prioritizes therapies in terms of treatment outcomes, i.e. it seeks to find the right treatment for a given condition. The intent of comparative effectiveness research is to help the nation’s payors identify and reimburse for treatments that have the best value and will likely go a long way to keep America healthy. Comparative effectiveness initiatives are gaining momentum under the Obama administration. The Aequitas Group can help you understand how comparative effectiveness research translates into reimbursement challenges and opportunities facing your specific therapeutic areas and identify strategies and tactics to capture market share. For insight on comparative effectiveness as it applies to your product portfolio, click here. Back to Insight© 2009 The Aequitas Group, Inc. All Rights Reserved.